Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 38,920 | +1,26 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum ersten Quartal auf "Buy" mit einem Kursziel von 50 US-Dollar belassen. Analyst Falko Friedrichs rechnet... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 16,640 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress | PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 44,000 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 | ||
EVOTEC | 14,180 | +3,50 % | Biotech Report: Evotec und Qiagen rutschen ab | (shareribs.com) Frankfurt / New York 16.04.2024 - Biotech-Aktien zeigen sich überwiegend leichter und folgen damit dem breiten Markt nach unten. Auch an der Wall überwiegen die negativen Vorzeichen... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,700 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 25,140 | +4,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
APOGEE THERAPEUTICS | 49,770 | +2,32 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
DISC MEDICINE | 27,000 | +0,07 % | Disc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On track to deliver multiple read-outs in 2024, including... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 17,680 | +3,42 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $370 - $390 million -- Abiprubart... ► Artikel lesen | |
MORPHOSYS | 67,75 | 0,00 % | Formycon, Defence Therapeutics, Morphosys - Mächtig Bewegung in der Biotechbranche | Aktuell richtet sich der Fokus der Anleger neben den wichtigsten Indizes wie DAX oder Dow Jones vor allem auf Gold oder Bitcoin, dagegen ist vom Biotechnologiesektor in den hiesigen Gazetten wenig zu... ► Artikel lesen | |
BIOMEA FUSION | 10,980 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
FUSION PHARMACEUTICALS | 21,360 | +0,19 % | Fusion Pharmaceuticals Inc. - 8-K, Current Report | ||
VERA THERAPEUTICS | 39,520 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 20,270 | +8,57 % | Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
NUVALENT | 67,56 | 0,00 % | Jefferies starts Nuvalent at buy, cites lung cancer drug candidates |